Search results for PX-TA1018

Denosumab Biosimilar – Anti-RANKL mAb – Research Grade, ProteoGenix, PX-TA1018

Description of Denosumab Biosimilar - Anti-RANKL mAb - Research Grade General information about Denosumab Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption markers in patients with a variety of metastatic tumors and is being investigated in multiple clinical trials for the prevention and treatment of bone metastases. Chemically, it consists of 2 heavy and 2 light chains. Each light chain consists of 215 amino acids. Each heavy chain consists of 448 amino acids with 4 intramolecular disulfides.This product is for research use only.